Sentence examples for Mylan pharmaceuticals from inspiring English sources
Mylan Pharmaceuticals does have an EpiPen Savings Card for eligible patients that reduces the cost of a carton by a maximum of $100.
Morgantown is home to the research centres of West Virginia University and to Mylan Pharmaceuticals, a generic-drug maker.
Immediate-release cysteamine bitartrate (Cystagon; Mylan Pharmaceuticals, Canonsburg, PA) may prevent or delay kidney transplantation and other serious outcomes in patients with cystinosis, but has never been subjected to a prospective clinical trial.
The most prominent case was in 2004, and it involved the Perry Corporation's purchase of shares in Mylan Pharmaceuticals, which was seeking to acquire King Pharmaceuticals at the time.
New York attorney general Eric Schneiderman has launched an investigation into Mylan Pharmaceuticals, the maker of EpiPens, after the company was revealed to have increased the price of its life-saving allergy medication and device by 471% since acquiring it in 2007.
Just look at how Mylan Pharmaceuticals has responded to the virtual evaporation of competitors to its lifesaving EpiPens by raising the price it charges for the auto-injector pens (which treat deadly allergic reactions to bee stings and food allergies) from $50 apiece to $600 for a two-pack over the course of eight years.
UPDATED 08/22/2016, including a statement from Mylan at the end] Mylan pharmaceutical company has a virtual monopoly on EpiPens after a voluntary recall felled their only competitor*, Sanofi's Auvi-Q, over possible dosage miscalibrations.
Under general anesthesia with 3.0% isoflurane (Mylan Pharmaceutical Inc., Tampa, FL, USA), lumbar IVDs were exposed through a posterolateral approach, the initial puncture with an 18-gauge needle was performed on two non-contiguous discs (L2/3 and L4/5), and the disc (L3/4) between punctured discs was left intact as a control [ 11].
Less biochemical wizardry is involved in generic drug production; his choices include Mylan, Par Pharmaceutical and a handful in Japan, where he expects generics to grow rapidly — Sawai Pharmaceutical, Nichi-Iko Pharmaceutical and Towa Pharmaceutical.
A point not mentioned by these advocates is that a big potential beneficiary of the campaign is Mylan, the pharmaceutical giant behind EpiPens.
Last month, when Mylan, a pharmaceutical company, agreed to acquire Abbott Laboratories Europeann generic-drug business and move its headquarters to the Netherlands, its C.E.O., Heather Bresch, explicitly noted that the deal had to do with lowering the company's taxes.
